Endocrine Abstracts

Background: Immune checkpoint inhibitors like monoclonal antibodies targeting programmed death 1 receptor (PD1) or its ligand (PD-L1) have shown antitumor activity in many malignancies by enhancing immune response against cancer cells resulting in significant long-lasting responses. However, this therapy can induce endocrine immune-related adverse events (EirAEs). Thyroid dysfunction is a common EirAE, while adrenal insufficiency (AI) is very uncommon.Ob...